Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9NYK5
UPID:
RM39_HUMAN
Alternative names:
39S ribosomal protein L39, mitochondrial; 39S ribosomal protein L5, mitochondrial
Alternative UPACC:
Q9NYK5; C9JYA5; Q32Q74; Q5QTR3; Q96Q65; Q9BSQ7; Q9BZV6; Q9NX44
Background:
The Large ribosomal subunit protein mL39, also known as 39S ribosomal protein L39, mitochondrial or 39S ribosomal protein L5, mitochondrial, plays a crucial role in the mitochondrial ribosome. Its primary function is to facilitate protein synthesis within the mitochondria, a process essential for cellular energy production and metabolic functions.
Therapeutic significance:
Understanding the role of Large ribosomal subunit protein mL39 could open doors to potential therapeutic strategies. Its pivotal role in mitochondrial protein synthesis makes it an intriguing target for addressing diseases linked to mitochondrial dysfunction.